scholarly journals Association between Carbonic anhydrase 9 expression and poor prognosis in sinonasal squamous cell carcinoma

2020 ◽  
Author(s):  
Lan Lin ◽  
Chunyan Hu ◽  
Huan Wang ◽  
Xicai Sun ◽  
Dehui Wang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Carbonic Anhydrase ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Poor Prognosis ◽  
Disease Free Survival ◽  
Curative Surgery ◽  
Positive Expression ◽  
Negative Prognostic Factor ◽  
Carbonic Anhydrase 9

Abstract Background: Carbonic anhydrase 9(CA9), as a member of the carbonic anhydrase enzyme family, was an endogenous marker of hypoxia. Previous studies suggested CA9 expression was correlated with poor prognosis in multiple types of malignancies. The purpose of current study was to evaluate the role of CA9 as a prognostic marker in sinonasal squamous cell carcinoma(SNSCC).Patients and methods: We assessed the immunohistochemical expression of CA9 in 63 tumor specimens of patients who underwent curative surgery and evaluated the relationship between the expression levels and clinicopathological factors as well as outcome.Results: We observed positive expression of CA9 in 21(33.3%) patients. Positive expression of CA9 in patients with SNSCC was significantly correlated with local recurrence (p=0.016) and both overall survival (OS) (p=0.003) and disease-free survival (DFS) (p=0.002). In Cox's multivariate analysis, CA9 expression was an independent negative prognostic factor for OS (p=0.027) and DFS (p=0.018).Conclusions: Our findings demonstrated that CA9 overexpression could be used as an independent prognostic biomarker and therapeutic target in SNSCC.

Overexpression of MMP-2 in laryngeal squamous cell carcinoma: A potential indicator for poor prognosis

2005 ◽  
Vol 132 (3) ◽  
pp. 395-400 ◽  
Author(s):  
Wei-Wei Liu ◽  
Zong-Yuan Zeng ◽  
Qiu-Liang Wu ◽  
Jing-Hui Hou ◽  
Yi-Yong Chen
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Poor Prognosis ◽  
Laryngeal Squamous Cell Carcinoma ◽  
Disease Free Survival ◽  
Clinicopathological Features ◽  
Cancer Center ◽  
Positive Expression ◽  
Survival Difference

OBJECTIVES: To investigate the expression and clinical significance of gelatinases (MMP-2 and MMP-9) in patients with laryngeal squamous cell carcinoma (LSCC). STUDY DESIGN AND SETTING: In a retrospective study of 72 consecutive patients with LSCC hospitalized in a single cancer center, immunohisto-chemistry was used to examine the expression of MMP-2 and MMP-9 in surgical samples. The results were compared to clinicopathological features and prognosis. RESULTS: The positive expression of MMP-2 and MMP-9 in patients with LSCC was 50% (36/72) and 73.6% (53/72), respectively. According to the expression scale, there were 36 patients of -, 26 patients of +, 7 patients of + +, and 3 patients of + + + expression of MMP-2; 19 patients of -, 26 patients of +,16 patients of ++, and 11 patients of + + + expression of MMP-9. There was no significant relationship found between the expression of MMP-2 or MMP-9 and clinicopathological features of LSCC, such as histological grade, primary site, T stage, N stage, and clinical stage. The 5-year overall survival (OS) and disease-free survival (DFS) rate calculated by Kaplan-Meier method in patients with negative and positive expression of MMP-9 and MMP-2 was 73.68%, 50.94%, 73.68%, and 49.06% in MMP-9 and 72.22%, 41.67%, 72.22%, and 38.89% in MMP-2, respectively. Significant 5-year survival difference was found between patients with negative and positive expression of MMP-2 (log rank = 6.74, P = 0.0094). There was significant lower survival rate in patients with higher positive expression of MMP-2 (log rank = 11.77, P = 0.0028). In glottic laryngeal cancer, positive expression of MMP-2 could predict poor survival and was more likely to present primary recurrence. CONCLUSION: The expression of MMP-2 could be used as a potential predictor for poor prognosis in patients with LSCC.

Clinicopathologic characteristics of HER2-positive metaplastic squamous cell carcinoma of the breast

2020 ◽  
pp. jclinpath-2020-206468
Author(s):  
Ting Lei ◽  
Tianjie Pu ◽  
Bing Wei ◽  
Yingying Fan ◽  
Libo Yang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Disease Free Survival ◽  
Clinicopathological Features ◽  
Lymph Node Status ◽  
Her2 Positive ◽  
Ki 67

AimsThe aim of this study was to analyse the clinicopathological features and prognosis of human epidermal growth factor receptor-2 (HER2)-positive metaplastic squamous cell carcinoma (MSCC).MethodsFifty-eight patients with MSCC of the breast who were classified into 45 triple-negative and 13 HER2-positive subgroups diagnosed at the West China Hospital, Sichuan University, from 2004 to 2018, were enrolled. Clinicopathological features were collected and compared between HER2-positive MSCC, triple-negative MSCC, HER2-positive invasive breast carcinoma of no special type (NST) and triple-negative NST groups. In the prognostic survival analysis, HER2-positive MSCCs was compared with triple-negative MSCCs, HER2-positive NSTs and triple-negative NSTs.ResultsCompared with triple-negative MSCCs, more patients with Ki-67 low expression were in HER2-positive MSCCs (p<0.05). More patients with HER2-positive MSCC than patients with HER2-positive NST were postmenopausal (p<0.05). Compared among HER2-positive MSCCs, triple-negative MSCCs and triple-negative NSTs, patients of HER2-positive MSCCs with high Ki-67 expression were the least, and HER2-positive MSCCs had more strongly associated with postmenopausal disease status (p<0.05). In survival analyses, HER2-positive MSCCs had a high risk of recurrence and poor prognosis (p<0.05). Lymph node status was significantly associated with the disease-free survival of patients with HER2-positive MSCC.ConclusionIn conclusion, our study indicates that HER2-positive MSCC is an aggressive disease with unique clinicopathological characteristics. Both HER2-positive status and an SCC component are critical factors for poor prognosis. HER2-positive MSCC and triple-negative MSCC are distinct subgroups. Corresponding targeted therapy recommendations should be made for this HER2-positive MSCC group.

Chemokine receptors seem to impact on patient survival in head and neck squamous cell carcinoma

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15527-15527
Author(s):  
M. H. Federico ◽  
C. M. Campofiorito ◽  
F. R. Mangone ◽  
S. Maistro ◽  
F. S. Pasini ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Chemokine Receptors ◽  
Disease Free Survival ◽  
Neck Squamous Cell Carcinoma ◽  
Ribonuclease Protection Assay ◽  
Curative Surgery ◽  
Tumor Spread

15527 Background and Methods: Chemokine receptors seem to be involved in tumor spread to lymph nodes and influence outcome in cancer patients (pts). Here, we have determined the mRNA expression of CCR7, CX3CR1 and CXCR1 chemokines, by means of Ribonuclease Protection Assay, in 60 fragments of primary tumor and matched adjacent mucosa of pts with head and neck squamous cells carcinoma (HNSCC) submitted to curative surgery. For Kaplan Meier survival curves, pts were categorized for each chemokine as positive or negative if above or equal/below median densitometric value of the entire tumor group. Results: In the whole study population, CCR7 status did not impact on overall survival (OS) (P=0.118, Log Rank) and on disease free survival (DFS) (P = 0.102), neither. When the subgroup of oral SCC was considered (n = 19), the CCR7 negative pts (n = 10) presented a longer DFS and OS (median DFS and OS not reached) as compared to CCR7 positive pts (n = 9) (mDFS: 4.9 months, P = 0.001 and mOS 10.47 months P = 0.003). In the HNSCC group as a whole, the CX3CR1 negative pts presented a trend toward longer OS (mOS 26.60 months in negative group, n = 25 vs 15.43 months in the positive group, n = 35, P = 0.073) and a longer DFS (mDFS not reached in CX3CR1 negative vs 9.20 months in positive pts, P = 0.041). In the oral SCC subgroup, CX3CR1 negative pts (n = 8) presented significantly better DFS (mDFS not reached) as compared to CX3CR1 positive pts (n = 11, mDFS 4.9 months, P = 0.004). OS was also superior for oral SCC CX3CR1 negative (mOS not reached) as compared to positive pts (mOS 10.47 months, P = 0.008). Taking into account larynx SCC, mDFS and mOS were not reached for CX3CR1 negative pts (n = 5) as compared to positive pts (n = 11, mDFS 8.57 months, P = 0.016; mOS 12.37 months, P = 0.041). In larynx subgroup, the other receptor associated to an advantage in terms of both DFS and OS was the negativity for CXCR1 (mDFS not reached for negative vs 8.47 months for positive pts, P = 0.006; mOS not reached for negative vs 8.47 months for positive pts, P = 0.025). Conclusions: Even if the mechanisms are not clear, our data suggest that low expression of CCR7, CX3CR1 and CXCR1 mRNA may be markers of better outcome in Head and Neck Squamous Cell Carcinoma. Further studies are warranted to confirm these results. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document